Strategies to Attenuate Myocardial Infarction and No-Reflow Through Preservation of Vascular Integrity by Pigment Epithelium-Derived Factor

Hum Gene Ther. 2022 Mar;33(5-6):330-345. doi: 10.1089/hum.2021.068. Epub 2021 Aug 27.

Abstract

The phenomenon of no-reflow seriously limits the therapeutic value of coronary recanalization and leads to poor prognosis. Recent studies have demonstrated the potential role of pigment epithelium-derived factor (PEDF) in stabilizing endothelial cell junction, reducing vascular permeability and maintaining a quiescent vasculature. In this study, intramyocardial gene delivery was performed 5 days before the acute myocardial infarction/recanalization experiment in male rats. Positron emission tomography perfusion imaging with 13N-NH3 indicated PEDF to promote microvascular reperfusion significantly 4 h postcoronary occlusion. PEDF was observed to maintain the stability of endothelial adherens junctions (AJs), thus preventing the occurrence of no-reflow. PEDF reduced the hypoxia-induced vascular endothelial (VE)-cadherin endocytosis through PEDF/LR/Src/VE-cadherin S665 axis in vitro, which was remarkably observed to maintain endothelial AJs. Generally, PEDF might function as a relevant target for therapeutic vasculoprotection by way of regulating the phosphorylation level of VE-cadherin according to our data, thus being crucial for preventing no-reflow.

Keywords: AMI; PEDF; microvascular damage; no-reflow.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Eye Proteins / genetics
  • Male
  • Myocardial Infarction* / therapy
  • Nerve Growth Factors / genetics
  • Rats
  • Serpins* / genetics
  • Serpins* / pharmacology

Substances

  • Eye Proteins
  • Nerve Growth Factors
  • Serpins
  • pigment epithelium-derived factor